Other
Decitabine-Primed Tandem CD19/CD20 CAR T Cells
0
Pipeline Programs↗
1
Active Trials↗
0
Companies Involved↗
Decitabine-primed Tandem CD19/CD20 CAR T Cells is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
2
clinical trials
Active, not recruiting1 · 50%
Unknown status1 · 50%
Clinical Trials
Trial Activity
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Active, not recruiting·—·Phase 1/2·NCT04697940·33 enrolled
Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden
Unknown status·—·Phase 1/2·NCT04553393·80 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)